OCU-10-C-110
/ Ocugenix
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 02, 2026
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
(clinicaltrials.gov)
- P1 | N=24 | Active, not recruiting | Sponsor: Ocugenix Corporation | Recruiting ➔ Active, not recruiting
Enrollment closed • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
March 21, 2025
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
(clinicaltrials.gov)
- P1 | N=19 | Recruiting | Sponsor: Ocugenix Corporation | Trial completion date: May 2025 ➔ Nov 2026 | Trial primary completion date: May 2025 ➔ Nov 2026
Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
November 13, 2023
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
(clinicaltrials.gov)
- P1 | N=19 | Recruiting | Sponsor: Ocugenix Corporation | Not yet recruiting ➔ Recruiting
Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
June 15, 2023
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
(clinicaltrials.gov)
- P1 | N=19 | Not yet recruiting | Sponsor: Ocugenix Corporation
New P1 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
1 to 4
Of
4
Go to page
1